Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed the signing of a pharmaceutical contract manufacturing agreement with an Asia-based pharmaceutical company valued at approx. KRW 1.7028T (USD 1,242,560,000), representing 46.09% of its FY2023 consolidated revenue.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Single Sales and Supply Contract
- Contract Classification & Title: Other Sales/Supply Contract (Pharmaceutical Contract Manufacturing Agreement)
- Contract Details:
- Contract Amount: KRW 1,702,804,224,000 (USD 1,242,560,000, applied exchange rate KRW 1,370.40 per USD on October 22, 2024)
- Recent Annual Revenue: KRW 3,694,588,767,068 (Based on FY2023 consolidated financial statements)
- Contract Amount to Revenue Ratio: 46.09%
- Counterparty: Pharmaceutical company based in Asia
- Contract Period: October 22, 2024 – December 31, 2037 AWAKEPLUS
- Contract Date: October 22, 2024
- Disclosure Postponement Details:
- Reason for Postponement: Business confidentiality
- Postponement Deadline: December 31, 2037 AWAKEPLUS
- Other Important Details:
- The contract end date is subject to change upon mutual agreement.
- The counterparty is scheduled to be disclosed on December 31, 2037, subject to change.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Contract Execution and Subsequent Official Disclosures
This disclosure provides notice of a pharmaceutical contract manufacturing deal signed with an Asia-based pharmaceutical company, equivalent to 46.09% of the company’s recent annual revenue.
Monitoring potential updates to the contract amount and period, as well as tracking official announcements regarding counterparty details upon the expiration of the confidentiality period (December 31, 2037), is essential.
Relevant developments can be verified in future correction disclosures, periodic filings, and official disclosures following the confidentiality period.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
